Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

L Padyukov, J Lampa, M Heimbürger, S Ernestam, T Cederholm, I Lundkvist, P Andersson, Y Hermansson, A Harju, L Klareskog, J Bratt, L Padyukov, J Lampa, M Heimbürger, S Ernestam, T Cederholm, I Lundkvist, P Andersson, Y Hermansson, A Harju, L Klareskog, J Bratt

Abstract

Background: Rheumatoid arthritis (RA) is a genetically complex disease where the response to different treatments varies greatly between different patients. This is the case with the tumour necrosis factor (TNF) blocking agents, where 20-40% of patients have been described as non-responders. No predictive markers exist as yet for the prognosis of response.

Objective: To analyse whether polymorphisms of several cytokine genes are associated with the responsiveness to TNF blockade with etanercept.

Methods: 123 patients with active RA were treated with etanercept and response rates were determined after three months using American College of Rheumatology (ACR)20 and disease activity score (DAS)28 response criteria. Genotyping was done for TNF (-308 TNFA), interleukin (IL)10 (-1087 IL10), transforming growth factor (TGF)beta1 (codon 25 TGFB1), and IL1 receptor antagonist (intron 2 IL1RN).

Results: 24 patients (20%) were defined as non-responders owing to their failure to fulfil any of the ACR20 or DAS28 response criteria. None of the recorded alleles was alone significantly associated with responsiveness to treatment. However, a certain combination of alleles (-308 TNF1/TNF1 and -1087 G/G) was associated with good responsiveness to etanercept (p<0.05). In addition, a combination of alleles influencing interleukin 1 receptor antagonist (IL1Ra) and TGFbeta1 production (A2 allele for IL1RN and rare C allele in codon 25 of TGFB1 gene) was associated with non-responsiveness (p<0.05).

Conclusion: Genetic polymorphisms, which may influence the balance of pro- and anti-inflammatory cytokines of relevance for the course of RA, are associated with clinical responsiveness to etanercept treatment.

References

    1. Ann Intern Med. 1992 Nov 15;117(10):801-6
    1. Kidney Int. 1999 Jul;56(1):281-8
    1. Arthritis Rheum. 1994 Aug;37(8):1166-70
    1. Nature. 1994 Oct 6;371(6497):508-10
    1. Clin Exp Immunol. 1995 Feb;99(2):303-10
    1. Arthritis Rheum. 1995 Jun;38(6):727-35
    1. Tissue Antigens. 1996 Sep;48(3):153-60
    1. Eur J Immunogenet. 1997 Feb;24(1):1-8
    1. Lancet. 1999 Dec 4;354(9194):1932-9
    1. Ann Rheum Dis. 2000 Jun;59(6):439-47
    1. N Engl J Med. 2000 Nov 30;343(22):1586-93
    1. Arthritis Rheum. 2000 Nov;43(11):2391-6
    1. N Engl J Med. 2001 Mar 22;344(12):907-16
    1. Gastroenterology. 2001 May;120(6):1347-55
    1. Genes Immun. 2001 Aug;2(5):280-3
    1. Arthritis Rheum. 1988 Mar;31(3):315-24
    1. Tissue Antigens. 1992 May;39(5):225-35
    1. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9
    1. Mol Immunol. 1997 Apr;34(5):391-9
    1. Transplantation. 1997 Sep 15;64(5):776-9
    1. Clin Immunol Immunopathol. 1998 Jun;87(3):309-13
    1. Transplantation. 1998 Oct 27;66(8):1014-20
    1. Arthritis Rheum. 1999 Apr;42(4):757-62
    1. Hum Genet. 1993 May;91(4):403-4

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir